Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED StatementS of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash flows from operating activities | ||
| Net loss | $(695,981) | $(116,914) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation expense | 2,887 | 3,528 |
| Non-cash lease expense | 5,647 | 5,041 |
| Stock-based compensation | 18,912 | 9,847 |
| Transaction costs for issuance of pre-funded warrants | 643 | — |
| Change in fair value of warrant liabilities | 334,358 | — |
| Interest amortization on marketable securities | (67) | (1,149) |
| Loss (gain) on sale of property and equipment | 3,303 | (18) |
| Issuance of pre-funded warrants in connection with the acquisition of in-process research and development | 177,377 | — |
| Changes in operating assets and liabilities: | ||
| Operating lease liabilities | (2,406) | (3,830) |
| Prepaid expenses and other current assets | 1,684 | (835) |
| Accounts payable and accrued liabilities | 10,930 | 2,241 |
| Other assets | — | 2,429 |
| Net cash used in operating activities | (142,713) | (99,660) |
| Cash flow from investing activities | ||
| Purchases of marketable securities | (53,660) | (9,914) |
| Proceeds from maturities of marketable securities | 5,000 | 107,000 |
| Purchases of property and equipment | (941) | (229) |
| Proceeds from sales of property and equipment | 799 | — |
| Net cash (used in) provided by investing activities | (48,802) | 96,857 |
| Cash flow from financing activities | ||
| Proceeds from the issuance of common stock from private placement | 149,999 | 55,550 |
| Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions | 108,101 | — |
| Proceeds from the issuance of pre-funded warrants from private placement | 175,000 | — |
| Payment of issuance costs related to underwritten public offering and private placements | (1,325) | (2,325) |
| Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs | 70,106 | 275 |
| Payment for tax withholdings upon vesting of restricted stock unit awards | (254) | (333) |
| Proceeds from stock option exercises and the issuance of shares under ESPP | 2,180 | 225 |
| Net cash provided by financing activities | 503,807 | 53,392 |
| Net increase in cash, cash equivalents and restricted cash equivalents | 312,292 | 50,589 |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | $84,362 | $33,773 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $396,654 | $84,362 |
| Supplemental disclosure of non-cash activities | ||
| Right-of-use assets obtained in exchange for lease obligations | $3,079 | $— |
| Financing costs associated with the sale of common stock included in accounts payable and accrued expenses | $127 | $563 |
| Unrealized gain on available-for-sale securities | $19 | $99 |
| Issuance of pre-funded warrants in connection with the acquisition of in-process research and development | $177,377 | $— |
A reconciliation of the cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows is as follows:
| For the Year Ended December 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash and cash equivalents | $396,486 | $81,949 |
| Restricted cash equivalents | 168 | 2,413 |
| Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows | $396,654 | $84,362 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.